Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin

Seong Yeol Choi¹†, Sungbin Lim¹†, Kyoung-hye Yoon²*, Jin I. Lee³* and Robert J. Mitchell¹*

Abstract

In this review, we discuss violacein and prodigiosin, two chromogenic bacterial secondary metabolites that have diverse biological activities. Although both compounds were "discovered" more than seven decades ago, interest into their biological applications has grown in the last two decades, particularly driven by their antimicrobial and anticancer properties. These topics will be discussed in the first half of this review. The latter half delves into the current efforts of groups to produce these two compounds. This includes in both their native bacterial hosts and heterogeneously in other bacterial hosts, including discussing some of the caveats related to the yields reported in the literature, and some of the synthetic biology techniques employed in this pursuit.

Keywords: Prodiginosin, Violacein, Antibacterial, Anticancer, Secondary Metabolite, Production, Synthetic Biology

Introduction

Bacterial strains are capable of producing many different secondary metabolites, including anti-cancer and antibiotic drugs. Here, we discuss two such compounds that are gaining interest due to their diverse biological activities, namely violacein and prodigiosin. Both of these compounds are synthesized by Gram-negative hosts and have been shown in studies from a wide berth of groups to possess important biological activities, including as potent antibiotics against multidrug resistant pathogens. Although both compounds were “discovered” nearly a century ago in the mid-20th century [1–3], their biological activities are still being studied to this day. However, one critical factor limiting research with either compound is their cost, which range from $360 to $760 per milligram [4]. Within this review, therefore, discussion will be given primarily to the biological activities of these compounds, focusing on ecological and medical considerations of both violacein and prodigiosin, as well as current methods to over-produce these remarkable compounds.

Violacein and Prodigiosin – Hydrophobic Bacterial Chromogenic Pigments

Prodigiosin and violacein are both colorful secondary metabolites, a trait that makes isolating and identifying the bacterial strains that produce these compounds in sufficient quantities easier. As shown in Fig. 1, violacein is a purple-hued bacterial pigment. The fact that this compound is produced by a range of natural bacterial strains [5–8], including Chromobacterium [9] and Janthinobacterium [10], and in a wide-array of environmental locales, including the deep seas [11], rivers [9, 12], agricultural and forest soils [8, 13, 14], within polar and alpine glacial regions [7, 15, 16], and even on the leaves of white
clover [17] and the skin of amphibians [18], all suggest the production of violacein should be relatively advantageous for the host. However, the octanol-water partitioning coefficient (Log P_{OW}) for violacein is 3.34 [19, 20], classifying this compound as highly hydrophobic and suggesting it is not readily secreted by the host into the surrounding environment.

Similarly, prodigiosin is vibrant red in color (Fig. 1) and is produced by a number of different Gram-negative and Gram-positive bacterial strains, including *Serratia marcescens* [21] and *Streptomyces*. As a compound, prodigiosin is a member of the prodiginines, a group of chemicals with the same parent nucleus but differing side groups. For this review, emphasis will be given primarily to prodigiosin as this is the most extensively studied compound within this group. When compared with violacein, prodigiosin is even more hydrophobic, with a Log P_{OW} of 5.16 [22].

**Violacein and Prodigiosin as Antimicrobials**

The antimicrobial activities of these two compounds have been extensively studied (Tables 1 and 2), particularly for violacein. It is historically recognized that very few Gram-negative bacteria are susceptible to violacein, data that is supported by independent groups in many recent studies [3, 39–41, 58]. The fact that violacein has been produced in recombinant strains of *E. coli*, as well as in *Salmonella typhimurium* VNP20009, *Enterobacter aerogenes* IAM1183 and *Citrobacter freundii* ATCC 05411, with no clear detriment to the growth or viability of these strains [59–62] supports this further. However, individual studies from some groups recently claim violacein exhibits low MIC or growth inhibitory activities with Gram-negative strains [63–65]. Given the historicity and wide range of reports suggesting otherwise, the veracity of these studies needs to be demonstrated independently by other research groups.

In contrast, the activity of violacein against many different Gram-positive bacterial strains (Table 1), including *Staphylococcus*, *Bacillus* and *Streptococcus* [3, 40], is well established. Despite this, its spectrum does not extend to all Gram-positive strains. For instance, *Enterococcus faecalis* ATCC 29212 was not affected by the addition of violacein [66], while *Corynebacterium glutamicum* ATCC 21850 was genetically engineered to produce violacein [67]. It also exhibits antibiotic activities against *Mycobacterium tuberculosis* and *M. smegmatis*, which are acid-fast microbes, and the Gram-variable *Micrococcus luteus* [7, 68].

Stemming from its recognized activities against Gram-positive strains, many recent studies have evaluated the use of violacein against antibiotic-resistant strains of *S. aureus* [8, 41, 58, 66]. For instance, the minimal inhibitory concentrations (MICs) for several *S. aureus* associated with Bovine Mastitis were between 6.25 and 25.00 μM violacein, even though these strains displayed
penicillin, ampicillin and/or intermediary erythromycin resistance [58]. Moreover, violacein acted synergistically with penicillin [58], an idea that was expanded on in another study [64]. A separate study using methicillin-resistant S. aureus (MRSA) reported MICs in basically the same range, i.e., 7.5 to 30 μM [66], while research from our group found a multidrug-resistant S. aureus clinical isolate with resistance to seven different antibiotics was also susceptible to violacein [8]. In that study, the MICs for both the clinical isolate and the non-resistant type strain (S. aureus ATCC 25923) were identical (15 μM) while bactericidal effects against both were seen when 30 μM or more violacein was employed [8]. This proved the antibacterial mechanism used by violacein differs from that of the other antibiotics and also that cross-resistance was not present.

For both compounds, their antimicrobial activities stem in part due to their lipophilic natures. When introduced into a bacterial culture, prodigiosin and violacein rapidly insert into the membranes of the microbe and disrupt their integrity, leading to ATP and protein leakage [22, 69, 70]. Interactions between violacein and bacterial membranes were recently modeled [70], and suggested that this compound does not embed very deeply within the lipid bilayer. The same study looked at the release of carboxyfluorescein from large unilamellar vesicles (LUVs) prepared using the lipids from three different bacteria, i.e., E. coli ATCC 25922, B. subtilis PY79 and S. aureus ATCC 25923. They found, regardless of the strain, the LUVs were equally susceptible [70], implying E. coli cellular membranes are just as likely to be attacked by violacein and that its inherent resistance to violacein stems from the protective nature of the outer membrane, which absorbs this antibiotic and prevents its access to the cytoplasmic membrane. Recent work from our group studied this further, but from a different perspective, by asking

### Table 1 Prodigiosin’s antibiotic activity against microorganisms

| Microbe                     | Description            | Reference |
|-----------------------------|------------------------|-----------|
| **Bacteria**                |                        |           |
| Bacillus cereus             |                        | [23]      |
| Bacillus subtilis           |                        | [24]      |
| Enterobacter cloacae        |                        | [25]      |
| Escherichia coli            |                        | [23, 25]  |
| Klebsiella aerogenes        | Human pathogen         | [23]      |
| Pseudomonas aeruginosa      | Human pathogen         | [25]      |
| Staphylococcus aureus       | Human pathogen         | [23, 25–27] |
| Streptococcus pyogenes      | Human pathogen         | [27]      |
| **Fungi**                   |                        |           |
| Batrachochytrium dendrobatidis | Amphibian pathogen  | [28]      |
| Batrachochytrium salamandrivorans | Amphibian pathogen  | [28]      |
| Botrytis cinerea            | Plant pathogen         | [29]      |
| Fusarium oxysporum          | Plant pathogen         | [30]      |
| Mucor irregularis           | Human pathogen         | [31]      |
| Mycosphaerella fijiensis    | Plant pathogen         | [32]      |
| Phytophthora infestans      | Plant pathogen         | [30]      |
| Pythium myriotylum          | Plant pathogen         | [30]      |
| Rhizoctonia solani          | Plant pathogen         | [30, 33]  |
| Sclerotium rolfsii          | Plant pathogen         | [30]      |
| **Virus**                   |                        |           |
| HSV-1                       | Herpes                 | [34]      |
| **Protozoa**                |                        |           |
| Plasmodium falciparum       | Malaria                | [35, 36]  |
| Trypanosoma cruzi           | Parasitic euglenoids   | [37]      |
| **Insect**                  |                        |           |
| Aedes aegypti               | Yellow fever mosquito  | [38]      |
| Anopheles stephensi         | Malaria vector         | [38]      |
how violacein acts as an antibiotic in nature if it is hydrophobic and remains embedded primarily within the membrane of the strain that produced it. It was found C. violaceum secretes violacein within membrane vesicles (MVs) [20]. These vesicles bud off of the bacterium as it grows and contained more violacein than proteins (mg/mg), increasing the apparent water solubility of violacein. Using S. aureus and a violacein-deficient viaA mutant, the violacein-carrying MVs were proven to be bactericidal, although a greater overall amount of violacein was required to achieve the same killing efficiencies as crude purified violacein. In contrast, MVs from the viaA mutant had no impact on S. aureus viabilities, proving violacein was the bactericidal factor responsible.

Table 2 Violacein’s antibiotic activity against microorganisms

| Microbe                | Description                  | Reference |
|-----------------------|------------------------------|-----------|
| Bacteria              |                              |           |
| Bacillus anthracis    | Anthrax                      | [3]       |
| Bacillus cereus       |                              | [39]      |
| Bacillus licheniformis|                              | [40]      |
| Bacillus megaterium   | Plant pathogen               | [3, 40]   |
| Bacillus mesentericus | Potential probiotics         | [3]       |
| Bacillus subtilis     | Common soil bacteria         | [3, 40]   |
| Corynebacterium diphtheriae |                        | [3]       |
| Neisseria meningitidis| Meningococcal disease       | [3]       |
| Pseudomonas aeruginosa| Human pathogen               | [40, 41]  |
| Staphylococcus aureus | Human pathogen               | [3, 39–41]| |
| Staphylococcus epidermidis|                        | [3, 39]   |
| Staphylococcus haemolyticus|                      | [3]       |
| Streptococcus pneumoniae | Pneumonia                  | [3]       |
| Viridans streptococci |                              | [3]       |
| Fungi                 |                              |           |
| Aspergillus flavus    |                              | [42]      |
| Batrachochytrium dendrobatidis | Amphibian chytrid fungus | [18, 28, 43, 44] |
| Batrachochytrium salamandrivorans | Amphibian chytrid fungus | [18, 28, 44] |
| Bipolaris leersia     |                              | [45]      |
| Botrytis cinerea      | Plant pathogen               | [45–47]   |
| Candida albicans      | Yeast                        | [42]      |
| Candida tropicalis    | Yeast                        | [42]      |
| Colletotrichum acutatum| Plant pathogen              | [47]      |
| Colletotrichum dematium| Plant pathogen             | [45]      |
| Colletotrichum glycines| Plant pathogen             | [46]      |
| Colletotrichum orbiculare | Plant pathogen, Affected by deoxyviolacein | [46] |
| Cryptococcus gastricus|                              | [42]      |
| Diaportha normaii     |                              | [45]      |
| Fusarium lateritum    | Plant pathogen               | [45]      |
| Fusarium oxysporum    | Plant pathogen               | [42, 46]  |
| Fusarium solani       | Plant pathogen               | [45]      |
| Gibberella zeae       | Plant pathogen, Affected by deoxyviolacein | [46] |
| Magnaporthe grisea    | Plant pathogen, Affected by deoxyviolacein | [46] |
| Penicillium expansum  | Plant pathogen               | [42]      |
| Phytophthora capsici  | Plant pathogen               | [46]      |

Table 2 Violacein’s antibiotic activity against microorganisms (Continued)

| Microbe              | Description                  | Reference |
|----------------------|------------------------------|-----------|
| Bacteria             |                              |           |
| Bacillus cereus      |                              | [39]      |
| Bacillus licheniformis|                              | [40]      |
| Bacillus megaterium  | Plant pathogen               | [3, 40]   |
| Bacillus mesentericus| Potential probiotics         | [3]       |
| Bacillus subtilis    | Common soil bacteria         | [3, 40]   |
| Corynebacterium diphtheriae |                        | [3]       |
| Neisseria meningitidis| Meningococcal disease       | [3]       |
| Pseudomonas aeruginosa| Human pathogen               | [40, 41]  |
| Staphylococcus aureus| Human pathogen               | [3, 39–41]| |
| Staphylococcus epidermidis|                        | [3, 39]   |
| Staphylococcus haemolyticus|                    | [3]       |
| Streptococcus pneumoniae | Pneumonia                  | [3]       |
| Viridans streptococci|                              | [3]       |

Virus

| Microbe            | Description                  | Reference |
|--------------------|------------------------------|-----------|
| HSV-1              | Herpes                       | [48]      |
| Poliovirus type 2  | Poliomyelitis               | [48]      |
| Simian rotavirus SA11| Rotavirus                | [48]      |

Nematode

| Microbe                | Description                  | Reference |
|-----------------------|------------------------------|-----------|
| Bursaphelencus xylophils| Pine wilt nematode           | [49]      |
| Caenorhabditis elegans|                              | [50, 51]  |

Protozoa

| Microbe             | Description                  | Reference |
|---------------------|------------------------------|-----------|
| Acanthamoeba castellanii| Amoeba                     | [6]       |
| Leishmania amazonensis| Leishmaniasis parasite     | [52]      |
| Plasmodium chabaudi | Malaria                     | [53]      |
| Plasmodium falciparum| Malaria                     | [53, 54]  |
| Rhynchomonas nasuta |                              | [6]       |
| Tetrahymena sp.     |                              | [6]       |
| Trypanosoma brucei gambiense| Human parasite | [55]      |
| Trypanosoma cruzi   | Human parasite               | [54]      |

Insect

| Microbe                  | Description                  | Reference |
|--------------------------|------------------------------|-----------|
| Drosophila melanogaster  | Fruit flies                  | [56]      |
| Spodoptera litura        | Plant pest insects           | [57]      |
A recent study also performed molecular dynamic simulations with prodigiosin [71]. The authors found, in contrast to violacein, prodigiosin embedded itself much deeper within the membrane lipid bilayer, a finding that helps explain why this compound is effective against some Gram-negative strains as this would increase the chances for prodigiosin to penetrate the outer membrane and enter the cytoplasmic membrane. However, it still remains to be seen if MVs are also used by prodigiosin-producing strains to transport this antibiotic to susceptible microbes.

In addition to membrane disruption, prodigiosin apparently causes additional damage within the bacteria, including the generation of reactive oxygen species (ROS) [23, 72] and, based on the study by Darshan and Manonmani (2016) [23], interacting with the bacterial genomic DNA. This latter facet of its activities corroborates an earlier study where prodigiosin was shown to cleave double-stranded DNA in vitro [73], an activity that is mediated by oxidative radicals (i.e., ROS) and requires the presence of a redox-active transition metal since the addition of either catalase or EDTA inhibited cleavage. Taken together, both studies suggest the ROS production by prodigiosin and its interactions with redox-active transition metals may act in concert in vivo to cause DNA damage within the bacterial cell, although this would benefit from further verification.

**Prodigiosin and Violacein as Antifungals**

In addition to their application towards bacterial pathogens, violacein (and its deoxyviolacein derivative) and prodigiosin also work widely and effectively against many pathogenic fungi (Tables 1 and 2). For violacein, representative examples of fungi that are susceptible include the plant pathogen *Rhizoctonia solani* [42, 46] and *Batrachochytrium dendrobatidis* [43, 44], a fungus that is lethal to amphibians. In the latter case, the presence of a violacein-producing bacterium, *J. lividum*, on the skin of the black-backed salamander (*Plethodon cinereus*) [44] or frog (Rana muscosa) [43] provided protection against *B. dendrobatidis*. Under these conditions, this bacterium was clearly able to produce a significant amount of violacein as the skin-associated concentrations with the frogs averaged around 100 μM, which was much higher than the 18 μM MIC needed to prevent mortality and morbidity caused by *B. dendrobatidis* based on the salamander study.

Although not studied as extensively, several reports have also discussed prodigiosin and its activities against different fungal species [30, 74–77]. Much like the two studies mentioned above, one group even looked at the ability of *S. marcescens* to protect *Acris Blanchardi* (Blanchard’s Cricket frog) from *B. dendrobatidis* infections, reporting a slight, yet significant, increase in survival rates when compared against a pig mutant that is unable to synthesize this compound [77]. Moreover, although the mechanism of action is not fully understood, detailed observation of *S. marcescens* invading into fungus was reported recently [31]. In that study, prodigiosin increased the membrane permeability of target cell, enabling *S. marcescens* to invade into *F. oxysporum*. Given prodigiosin’s ability to damage the target cell’s membrane was also suggested as a mechanism of action against other bacterial cells [22], it would appear this compound has similar properties against organisms spanning different kingdoms.

**Violacein and Prodigiosin as Nematicidal and Anti-Protozoan Agents**

A benefit of violacein and prodigiosin for the producing bacteria is that it confers a survival advantage against competitors and predators, providing selective advantages against neighboring bacteria and an effective defense and deterrent against bacterivores, such as protozoa and nematodes (Tables 1 and 2).

Nematodes have caused detrimental disease to both humans and agriculture worldwide. Pine wilt disease, a serious epidemic that has devastated pine forests globally, especially in East Asia, is caused by the nematode *Bursaphelenchus xylophilus*. This nematode, also called pine wilt nematode, attacks the water transport system of pine trees, causing them to wilt and die [78]. Expensive nematicides have commonly been used to combat pine wilt nematode with little success. Recently, a violacein5-O-glucoside derivative was constructed by expressing the glycosyltransferase (*YjIC*) from a *Bacillus* sp. in *E. coli* along with the *viaABCDE* [49]. This novel violacein derivative had increased water solubility and was an effective treatment against the pine wood nematode [49], suggesting its potential use in the future as an anti-nematodal agent against pine wilt disease.

Violacein also negatively impacted the nematode genetic model organism *C. elegans*. When fed on violacein-producing *Janthinobacterium*, *C. elegans* displayed developmental arrest in early larval stages [50]. Similar developmental arrest and delay was seen when violacein was expressed in *E. coli* OP50 [79] (Fig. 2), the normal laboratory diet of *C. elegans* [50]. Consumption of this compound induced the expression of several detoxification genes regulated by the insulin-like signaling pathway [80]. Interestingly, supplementation of unsaturated fatty acids, especially oleate, alleviated the worm growth and survival in violacein, whereas saturated fatty acids had no effect [79]. In addition to highlighting the anti-nematodal potential of violacein, studies in *C. elegans* may help also elucidate if a conserved mechanism of violacein-induced toxicity in metazoans exists. With the extensive genetic and molecular tools available for *C.
elegans, exploring how unsaturated fatty acids are able to mitigate violacein’s toxicity may provide a window into this mechanism, and may also shed light on its activities within cancer cells.

Anticancer Activities of Prodigiosin and Violacein

Another well-known characteristic of these two compounds is their anti-tumor activities. Cancer is the second leading cause of death globally [81], and although recent therapeutics have been developed for some cancers, still it remains as devastating as ever. In the laboratory, prodigiosin has been reported to kill human cancer cell lines by a process called programmed cell death or apoptosis. Prodigiosin can induce apoptosis in hematopoietic cancer cells [82], human lung cancer cells [83], B cells and T cells in chronic lymphocytic leukemia [84], gastric cancer cells [85], multidrug resistant breast cancer cells [86], colorectal cancer cells [87] and glioblastoma multiforme cancer cells [88] (Table 3).

Despite the strong evidence that prodigiosin can work against multiple types of cancer cells, how this compound targets cancer cell death by apoptosis is not yet clear. Prodigiosin can interact with and cleave DNA [73, 92], supporting one possible mechanism of cell death. Prodigiosin also facilitates proton and chloride ion symport and can affect the acidification of cellular compartments [94, 95], providing support for an alternative mechanism of cancer cell apoptosis [90]. Finally, prodigiosins also inhibit protein phosphatase activity in vitro [96, 97], suggesting another possible mechanism of how this compound may inhibit cancer cell growth.

More recent studies have suggested that prodigiosin causes cell death by affecting a cellular process called autophagy. The process of autophagy causes an accumulation of specific vesicles in the cell called autophagosomes that can break down damaged organelles or proteins [98]. Autophagy has also been a target

Table 3 List of cell lines evaluated with prodigiosin

| Cell Line | Description | References |
|-----------|-------------|------------|
| 95-D      | Human highly metastatic lung cancer | [89] |
| B-CLL     | Chronic lymphocytic leukemia | [84] |
| DLD1      | Colorectal cancer | [87] |
| GLC4      | Small cell lung cancer | [83] |
| A549      | Lung cancer | [90] |
| HCT116    | Colorectal cancer | [87, 91] |
| SW480     | Colorectal cancer | [87, 91] |
| SW620     | Colorectal cancer | [87] |
| HGT-1     | Gastric cancer | [85] |
| HL-60     | Haematopoietic cancer | [73, 82] |
| Jurkat    | Haematopoietic cancer | [82, 92] |
| U87MG     | Glioblastoma cancer | [88] |
| GBM8401   | Glioblastoma cancer | [88] |
| MCF-7     | Breast cancer | [86, 92] |
| MDA-MB-231| Breast cancer | [86, 93] |
| NSO       | Haematopoietic cancer | [82] |
| Ramos     | Haematopoietic cancer | [82] |
for cancer therapy [99], especially due to the fact that this cellular process also regulates apoptosis in cancers [100]. In a recent laboratory study, prodigiosin treatment induced the death of glioblastoma cancer cells and reduced neurosphere growth, a marker associated with increased death in glioblastoma patients [88]. The authors further showed that apoptotic death of the glioblastoma cells by prodigiosin treatment was due to increased autophagy in the cancer cells. In another recent study, colorectal cancer cells that were treated with the chemical 5-fluorouracil, a common chemotherapy treatment for colorectal cancer, showed increased apoptosis in the presence of prodigiosin [91]. Interestingly, prodigiosin impaired autophagic flux which actually promoted cell death in the cancer cells in response to 5-fluorouracil.

Combination therapy, which uses two or more therapeutic agents as a cancer treatment, has become a main strategy in cancer therapy in recent years [101]. The use of prodigiosin in combination with other cancer therapies is a promising strategy that is currently being explored. As mentioned previously, 5-fluorouracil in combination with prodigiosin effectively killed colorectal cancer cells by increasing apoptosis [91]. In addition, a recent study showed that the combination of prodigiosin and PU-H71, a candidate therapy for triple negative breast cancer, induced apoptosis in a metastatic breast cancer cell line killing many of the cancer cells [93]. These studies, as well as others, confirm that prodigiosin promotes the killing of cancer cells in the laboratory and demonstrate that it is an excellent candidate for cancer therapy either as a combination therapy or singular treatment. However, whether this activity can actually translate to a treatment for cancer patients remains unknown. Several phase I and phase II clinical studies with various cancer patients have occurred with a prodigiosin derivative called obatoclax [102–105], and the jury is still out on whether prodigiosin is an effective therapy for human cancer patients.

Similar with prodigiosin, violacein is also a promising anti-tumor bacterial metabolite (Table 4). As with prodigiosin, violacein leads to mitochondrial dysfunction, brought on by mitochondrial membrane hyperpolarization, in MRC-5 and HeLa cells [111]. It was also confirmed in RAS-mutated metastatic melanoma cell lines that the autophagy process employed to resolve mitochondrial damage is impaired due to inhibition of AKT and AXL [115]. Subsequent processes followed a general apoptotic pathway leading to p38 MAP kinase phosphorylation, NFKB pathway activation, and activation of caspases when treated with 1 μM of violacein in HL60 [113]. However, in TF1, which is known to have apoptosis resistance, the IC50 was still only 2 μM despite cotreatment with inhibitors of pro-apoptotic caspases, leading the authors to conclude that violacein induces cell death via the activation of a non-canonical mechanism of cell death [116]. Interestingly, an in vitro study showed that violacein inhibits PKA and PKC activity [117]. While the results do not exclude other possible targets, and whether this leads to cancer cell death in vivo awaits to be examined, it suggests PKA and PKC could be a direct target of violacein.

**Table 4 List of cell lines evaluated with violacein**

| Cell Line | Description | Ref |
|-----------|-------------|-----|
| 92.1      | Uveal melanoma | [106] |
| A549      | Lung cancer   | [60, 107] |
| A431      | Skin cancer   | [60] |
| Caco-2    | Heterogeneous epithelial colorectal adenocarcinoma | [108, 109] |
| CAL-27    | Head and neck carcinoma cells | [110] |
| CHO-K1    | Chinese Hamster Ovary cells | [111] |
| DLD1      | Colorectal adenocarcinoma | [109] |
| EAT       | Mouse Ehrlich ascites tumor | [112] |
| FaDu      | Head and neck carcinoma cells | [110] |
| FRhK-4    | Fetal kidney  | [48] |
| HCT116    | Colorectal adenocarcinoma | [60, 109] |
| HeLa      | Hela cell, Cervix cancer | [60, 111] |
| Hep2      | Hela-derived  | [48] |
| HL60      | Promyelocytic leukemia | [113] |
| HNS       | Head and neck squamous cell carcinoma cells | [60] |
| HT29      | Colorectal adenocarcinoma | [60, 108] |
| K562      | Lymphoma      | [113] |
| KM12      | Colon cancer  | [114] |
| MA104     | Monkey Kidney epithelial cells | [48] |
| MCF7      | Breast cancer  | [60, 107] |
| MOLT-4    | Acute lymphoblastic leukemia | [114] |
| MRC-5     | Fetal lung fibroblast | [111] |
| NCI-H460  | Non-small-cell lung cancer | [114] |
| OCM-1     | Choroidal melanoma | [106] |
| PC3       | Prostate cancer | [60] |
| SALTO     | Head and neck carcinoma cells | [110] |
| SCC-15    | Head and neck carcinoma cells | [110] |
| SKMEL-103 | RAS-mutated metastatic melanoma | [115] |
| SKMEL-28  | RAS-mutated metastatic melanoma | [115] |
| SW480     | Colorectal adenocarcinoma | [109] |
| TF1       | Erythroleukemia | [116] |
| U87       | Glioblastoma   | [107] |
| U937      | Chronic myelogenous leukemia | [113] |
| V79       | Chinese Hamster Fibroblast-like cell line from lung tissue | [114] |
| Vero      | Monkey Kidney  | [48] |
This sequence of cell death mechanisms resulting from mitochondrial damage brought on by violacein is due to the profound threat to the energy metabolism of cells. As a good indication of this, violacein has enhanced anti-cancer activities against some cell lines in hypoxia, such as HCT 116 (4.8-fold), HN5 (6.5-fold), HT29 (12.6-fold), and MCF7 (4-fold) [60]. Moreover, violacein treatment (1μM) led to the downregulated expression of chemokine/receptor CXCL12/CXCR4, which is important for angiogenesis [118]. Since carcinoma development without angiogenesis leads to hypoxic conditions, these results suggest violacein may actually induce the conditions within the tumor that increase its effectiveness as an anticancer agent, as was reported in one study [119].

Other studies have confirmed that oral administration of violacein contributes to NSAID-induced gastric damage healing. This led to a decrease in inflammatory cytokines, particularly TNF-α, and an increase in epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) [120]. These appear to play an essential role in healing angiogenesis and mucin secretion. In other words, violacein administered orally plays a role in inhibiting inflammation, maintaining the balance of cytokines, while also inhibiting apoptosis, angiogenesis, and promoting healing.

### Immunomodulatory Activities of Prodigiosin and Violacein

Prodigiosin is also known to have immunosuppressive effects. Specifically, this compound shows suppressive effects on T-cell proliferation, while having no effect in B-cells [121]. Its mechanism of action is to inhibit expression of the interleukin-2 receptor α(IL-2Ra) chain, an important contributor of T-cell activation [122]. In another study, the authors developed a prodigiosin-analogue molecule, PNU156804, which suppressed both T-cell and B-cell activation [123]. This compound also worked through inhibiting IL-2 dependent signaling, i.e., not by preventing IL-2Ra induction but rather by preventing activation of AP-1 and NF-κB. Prodigiosin was also synergistically active when administered with cyclosporine A, each working through different pathways to suppress T-cell activation [124], while another study found it inhibited macrophage and NK killer cell activities and splenocyte proliferation [125].

Violacein was also shown to have immunomodulatory functions and inhibit inflammation. For instance, this compound had antipyretic, analgesic, and immunomodulatory reactions when orally administered to rats [126]. In ulcer rat models, violacein relieved inflammation of the gastrointestinal tract, possibly working through the COX-1 mediated pathways [120], while another study reported that, when injected directly into the intraperitoneal cavity, violacein can have immunomodulatory effects by regulating cytokine production: it down-regulated the expression of IL-6 and TNF-α but induced expression of IL-10 [127].

Some of the immunomodulatory mechanisms and findings associated with violacein seem contradictory with the cancer studies, however. Unlike the above study that reported violacein inhibits TNF-α expression [127], TNF-α expression was elevated in HL60, and TNF receptor 1 signaling was also activated when this cell line was exposed to violacein [113]. It is also known to increase the expression of TNF-α and upregulate the p53-dependent mitochondrial pathway in MCF-7 [128], while treatment with violacein also induced TNF-α expression in Raw 264.7 and ANA-1 cells [129]. These differences may be due to the experimental protocols, though, as the above studies were performed in vitro, i.e., violacein treatment directly into human or murine cell cultures [128, 129], rather than in vivo, i.e., the oral administration or injection of violacein into the digestive tract or intraperitoneal cavity [120, 126, 127]. In other words, vastly different results may result depending on the method of administration and the type of cells, but all of the above studies confirmed that violacein has immunomodulatory aspects.

### Bioproduction - Measurement of Prodigiosin and Violacein – Spectrophotometry vs. HPLC

The classical method for prodigiosin extraction from the bacterial host and culture is to use acidified ethanol (4% 1M HCl v/v) to prevent the rapid decomposition of this molecule when above pH 5. The impurities present in the extracted prodigiosin are then removed using a solvent such as dichloromethane or n-hexane:chloroform and the final product purified through chromatography [130–132].

The simplest way to measure the extracted prodigiosin is to use a spectrophotometer using an absorption wavelength of 530-540 nm and convert this to the concentration using an extinction coefficient (ε) and the Beer–Lambert law. However, this is not without issue as the value of ε varies from study to study. Traditionally, the value of ε₅₃₅ is 0.159 L/mg-cm [133]. The most detailed study on the extinction coefficient of prodigiosin is Domröse et al. (2015) [130], where ε₅₃₅ was calculated to be 0.4322 L/mg-cm in acidified ethanol, a value that was confirmed through quantitative 1H-NMR. This value is near identical with that reported by another group, i.e., ε₅₃₅ = 0.4311 L/mg-cm [134]. Consequently, due to the difference in the extinction coefficients, the prodigiosin concentration using the classical ε value will be over-estimated by 270%.

Similarly, violacein has often been quantified using a spectrophotometer and its absorbance peaks at 575-
590 nm [8, 135–137]. However, because of differences in reported $\varepsilon$ between research groups, the yields claimed in the literature are inconsistent. For example, the $\varepsilon$ values for violacein include, from lowest to highest, $\varepsilon_{570} = 10.955$ L/g-cm in ethanol [138], $\varepsilon_{29.700}$ L/g-cm [137], $\varepsilon_{565} = 31.3$ L/g-cm in acetone-water [139], $\varepsilon_{570} = 46$ L/g-cm in ethanol [67], $\varepsilon_{575} = 56.010$ L/g-cm in ethanol [135] and $\varepsilon_{575} = 74.3$ L/g-cm in ethanol [140]. This disparity was raised in the study by Rodrigues et al. (2013) [140] and in previous reviews [141, 142], potentially inflating the violacein yields by as much as 670%.

To address this issue, Rodrigues et al. (2013) [140] elected to quantify violacein through HPLC [140], a protocol that has been successfully applied within several of our own studies [20, 143, 144]. At present, similar protocols have not been applied to quantify prodigiosin and HPLC may consolidate the yields in the literature, an idea that should be evaluated further. However, given the wide-spread problems raised by this issue, the concentrations of these two compounds reportedly produced in the literature will not be discussed, but rather the qualitative results of the studies.

**Production by Natural Isolates**

As discussed above, a wide-range of natural bacterial strains are capable of synthesizing violacein and prodigiosin. It should come as no surprise, therefore, that researchers have sought out a variety of strains for the lab scale production and application of these two compounds. For instance, *S. marcescens* FZSF02 was isolated from the soil in the region of Fuzhou, China, and is capable of producing prodigiosin in sufficient quantities that it reportedly pellets out of solution [145]. Another natural strain, *S. marcescens* MO-1 was isolated from a grasshopper [146] while *S. marcescens* UCP1459 and *S. marcescens* UTM1 were isolated from semi-arid soil in Brazil and an oxidation pond in Malaysia, respectively [147, 148]. A related bacterium, *S. rubidaea*, also produced prodigiosin and was initially isolated from a spoiled coconut, where it was discovered since it changed the color of the inside of the coconut, making it pink [149].

Similarly, violacein production has been studied in different natural strains. For instance, production of this compound in *C. violaceum* CCT 3496 was increased around 2.5-fold when tryptone and yeast extract were added, but the yields dropped with glucose [135]. In a separate study, optimization in *Duganella* sp. B2 found tryptophan, beef extract, and potassium nitrate were all major factors impacting violacein yields [138] while in *Massilia* sp. EP15224, an isolate known to be closely related to *Duganella* sp., the MM2 broth used to cultivate this strain was improved by adjusting the amount of phosphate, leading to faster production rates and slightly better final violacein yields [150].

Some violacein-producing bacteria are also psychrophilic, such as strain RT102, which is related with *J. lividum*, reported by Nakmura et al (2003) [40]. The authors found that the conditions leading to optimum production levels were a slightly acid pH of 6, the growth temperature set to 20°C and with 1 mg/L of dissolved oxygen. Although not as psychrophilic as RT102, *J. lividum* was also successfully used to produce violacein, albeit at 25°C and a pH of 7.0 [65]. Notably, in this study, the addition of 0.2 mg/mL of the antibiotic of silver ampicillin improved the yields by a factor of 1.3 while glycerol was used as a carbon source, a choice the authors claimed improves the violacein production relative to the cell mass.

The idea of using ampicillin and glycerol to increase violacein yields was actually reported more than a decade earlier in the study by Pantanella *et al* (2007), where glycerol enhanced violacein production levels by approximately 12-fold, while ampicillin led to an estimated 3-fold increase [136]. These factors, unfortunately, were not additive when used together – the maximum level with glycerol with or without ampicillin were basically identical.

The use of more natural feed stocks was also considered, as in the case with *C. violaceum* UTM5 where agricultural wastes were used [151], or in a separate study where liquid pineapple waste was used as the carbon source along with addition of L-tryptophan [41]. However, as noted above, since these papers do not provide the extinction coefficient and did not use HPLC techniques when quantifying their yields, it is difficult to directly compare their results with other studies.

**Random Mutations to Enhance Prodigiosin Production**

One strategy used by researchers to enhance production of prodigiosin is to generate random mutations within the genome of the natural host, typically with radiation. Since prodigiosin is a red pigment, screening is a simple and quick method for researchers to identify those colonies that overproduce this compound based on their color intensity. This was successfully used by one group with microwave irradiation to increase the prodigiosin yields from *S. marcescens* jx1 by just over two-fold [26], while a separate group used gamma irradiation [152]. In the latter study, the authors varied more than just the radiation dose and rate, including the pH and inoculum size, to identify conditions that optimize for prodigiosin production. However, as in the microwave radiation study, the yields were only improved by about 2-fold.
Heterogeneous Expression and Metabolic Pathway Engineering to Increase Prodigiosin and Violacein Yields

The above yields, although definitely improved, are not very significant and highlight potential limitations linked with random mutation studies, namely that improvements may not be very substantial, particularly when they involve complex metabolic pathways encoded in multiple genes such as those involved in prodigiosin biosynthesis. As such, researchers have often sought to clone and express the genes in other hosts where the metabolic and biosynthetic pathways can be engineered.

The prodigiosin gene cluster (pig) includes many genes, pigA to pigN, but may vary in gene order as well as include some auxiliary genes depending on the bacterial host [153, 154]. During the mid-20th century, studies in prodigiosin biosynthesis focused on related molecular components and constructing the pathway [21, 155–157], including the role of quorum sensing mechanisms [158–161], while recent studies have provided a more detailed understanding of the biosynthetic pathways involved [153, 154]. Violacein research has followed a similar path, with the biosynthetic pathway first mapped in 1991 [162] and the roles of the individual genes and enzymes characterized further in the early 2000’s [163, 164]. In addition, during the same period many articles, were published discussing the roles of quorum sensing in the production of this metabolite [165–167]. This led to the eventual development and application of C. violaceum CV026 as a quorum-sensing reporter strain, as it visually responded to the presence of acyl homoserine lactones (AHLs) with the production or inhibition of violacein synthesis [166, 168, 169]. Recently, this strain was reclassified as C. subtsugae [170].

As the last two decades have seen sequencing techniques and comparative genome analyses dramatically improve, a new era of prodigiosin and violacein production has opened. Gene clusters related with prodigiosin production were sequenced, analyzed and compared among different species and subspecies [171, 172], as have the genomes of numerous violacein-producing bacteria [173–175], particularly by Dr. Brooke Jude at Bard University who, in the last couple of years, has published several genomes [176–179]. Of particular note, one of the Janthinobacter sp. sequenced by her group actually lacked the genes for violacein but carried the pig gene cluster, allowing it to produce prodigiosin [180]. They concluded that, since this strain was isolated from the region where other violacein-producing strains were also located, including other Janthinobacter sp., the production of prodigiosin by this strain may represent a combined effort by the two groups to combat other bacterial species.

All of this information will aid researchers in further efforts to clone and express the genes required in other bacterial strains. This is not to say that this has not been done already, as a few groups reported the heterogeneous production of prodigiosin [130, 181], one as far back as 1984 [182]. However, only one study truly sought to use the new host, in this case Pseudomonas putida KT2440, as a platform for the production of this compound [130]. In their study, the authors introduced the pig cluster randomly into the genome of P. putida using a plasmid bearing a transposon and screened the resulting clones for prodigiosin production, looking for insertions where the cluster was expressed by a strong promoter. Using this method, they were able to increase prodigiosin production on agar plates by approximately five-fold over the original S. marcescens and as much as 94 mg/L, based on their quantification methods, in liquid cultures.

In contrast, the expression of violacein in other bacterial hosts is widespread, with the viaABCDE genes cloned and expressed within many plasmids and bacterial hosts. Some examples of this include Citrobacter freundii [61, 62], Klebsiella aerogenes (formerly Enterobacter aerogenes) [62] and E. coli [62, 140, 162, 183–185]. Other studies have sought to improve on the violacein yields through synthetic biology, often with E. coli as the host [54, 186], albeit not always for purification, as illustrated in two recent studies where its expression was used as a bioreporter [187, 188]. One prime example where synthetic biology was employed to improve violacein production is the study by Jeshek et al. (2016) where they introduced the Reduced Libraries algorithm [189]. These used this system to design smart combinatorial libraries for pathway optimization based on the ribosomal binding sites and, in this case, focused on increasing violacein production while minimizing that of deoxyviolacein. A second group used a different approach and elected to express each gene independently by their own promoter [59]. By controlling the strengths of each individual promoter, and using a combinatorial assembly of the genes, they were able to increase the violacein titers by more than 60-fold over the control, where each gene was expressed under the T7 promoter. In addition to E. coli, other hosts have been used for the heterogeneous production of violacein, including yeasts [190, 191]. One such study used Yarrowia lipolytica, an oleaginous yeast, as the host, where the vio genes were expressed using three different promoters and assembled using the Golden Gate assembly method to build combinatorial pathway libraries [191]. From this, three yeast strains, each producing a different chromogenic compound, i.e., violacein, deoxyviolacein and proviolacein, were constructed.
Conclusions

This review presented many biological traits of both prodigiosin and violacein reported in the recent and current literature. Fig. 3 is a plot showing the number of peer-reviewed articles listed in the National Center for Biotechnology Information’s PubMed website [192] for each year, providing visual evidence of the growing interest into these two compounds and their activities. Although the numbers may not be as great as some other hot-topics, the data makes it clear that many research groups continue to study and explore the biological activities of these two compounds and different methods for producing them in greater quantities. As this field continues to expand and mature, other derivatives of violacein and prodigiosin are expected to move towards clinical trials as antimicrobials and for the treatment of human diseases, including cancer, as was noted above for obatoclax. This will be supported in no small part by synthetic biologists and chemical engineers who are currently developing novel and more efficient protocols and strains to increase the productivity and yields of these two secondary metabolites, a trend that is also expected to reduce the costs of these compounds, which at present are too high for conventional medical research.

Acknowledgements

Funding was provided through the National Research Foundation of Korea under the Mid-Career Project (Grant No. 2020R1A2C2012158), the General Research Project (Grant No. 2020R1F1A1073848), and the Early Career Research Project (Grant No. 2019R1C1C1008708). We appreciate the support.

Availability of data and materials

None.

Declarations

Ethics approval and consent to participate

None.

Consent for publication

All authors agree with publishing this article within The Journal of Biological Engineering

Competing interests

The authors declare no competing interests with the publishing of this article

Received: 25 January 2021 Accepted: 3 March 2021

Published online: 11 March 2021

References

1. Wasserman HH, Mc KJ, Santer UV. Studies related to the biosynthesis of prodigiosin in Serratia marcescens. Biochem Biophys Res Commun. 1960;3(1):146–9.
2. Rapoport H, Holden KG. The Synthesis of Prodigiosin. J Am Chem Soc. 1962;84(4):635–42.
3. Lichstein HC, Vandesand VF. Violacein, an Antibiotic Pigment Produced by Chromobacterium-Violaceum. J Infect Dis. 1945;76(1):47–51.
4. Sigma-Aldrich U.S. website. https://www.sigmaaldrich.com/. Accessed 20 Jan 2021.
5. Yang LH, Xiong H, Lee OQ, Qi SH, Qian PY. Effect of agitation on violacein production in Pseudoalteromonas luteoviolacea isolated from a marine sponge. Lett Appl Microbiol. 2007;44(6):625–30.
6. Matz C, Webb JS, Schupp PJ, Phang SY, Penesyan A, Egan S, Steinberg P, Kjelleberg S. Marine biofilm bacteria evade eukaryotic predation by targeted chemical defense. PLoS One. 2008;3(7):e2744.

Authors’ contributions

SYC, SL, KHY, JIL and RJM wrote the article. The author(s) read and approved the final manuscript.
7. HKayak S, Fajrelk E, Klinkenberg G, Borges SEF, Josefse K, Ellingsen TE, Zotchev SB. Violacin-producing Collomias sp from the sea surface microlayer of coastal waters in Trondelag, Norway. Mar Drugs. 2009;7(4):576–88.

8. Choi SY, Kim S, Lyu A, Kim SB, Mitchell RJ. High-level production of violacin by the newly isolated Duganella violaceina strain N28 and its impact on Staphylococcus aureus. Sci Rep. 2015;5:15598.

9. Moss MO, Ryall C, Logan NA. Classification and Characterization of Chromobacteria from a Lowland River. J Gen Microbiol. 1978;105(3):11–21.

10. Otsuljan J, Mccollough J, Johnson JH, Bonner DP, Clark JC, Dean L, Trejo WH. Janthinocin-a, Janthinocin-b and Janthinocin-c, Novel Peptide Lactone Antibiotics Produced by Janthinobacterium-Biludium. J Taxonomy, Fermentation, Isolation, Physicochemical and Biological Characterization. J Antibiot. 1990;43(8):913–9.

11. Yada S, Wang Y, Zou Y, Nagasaki K, Hosokawa K, Osaka I, Arakawa R, Enamoto K. Isolation and characterization of two groups of novel marine bacteria producing violacin. Mar Biotechnol. 2008;10(2):128–32.

12. Rivas O, Hauen M, Duran N. Effect of Growth-Conditions on Production of Violacin by Chromobacterium-Violaceum (Bb-78 Strain). Braz J Med Biol Res. 1988;21(5):553–60.

13. Aranda S, Montes-Borrego M, Landa BB. Purple-Pigmented Violacein-Producing Duganella sp. inhabit the Rhizosphere of Wild and Cultivated Olives in Southern Spain. Microb Microbiol. 2011;62(2):446–59.

14. Li WJ, Zhang YQ, Park DJ, Li CT, Xu LH, Kim CJ, Jiang CL. Duganella cinereus. J Chem Ecol. 2008;34(11):1422–32.

15. Aranda S, Montes-Borrego M, Landa BB. Violacein-containing Bacterium, Serratia marcescens Strain B2 against Gray Mold Pathogen, Bacterially Produced Metabolite Violacein Is Associated with Survival of Trypanosoma cruzi: the role of Serratia marcescens. J Gen Microbiol. 2012;194(8):2096.

16. Li W, Zhang Y, Qu J, Wang K, Wang X, Shi B, Gao F, Liu J, Sun S, Li H, Hse CY, Shupe T, Zhou D, Zhao K. Animal Cell Death Revealing Molecular Biomarkers of Programmed Cell Death. AMB Express. 2016;6(1):50.

17. Baricz A, Teban A, Chiriac CM, Szekeres E, Farkas A, Nica M, Dascălu A, Moicănu A, Cârciu D. Antimicrobial properties of prodigiosin producing rhizospheric Serratia sp. DEC-B5. Korean J Microbiol. 2016;52(2):212–9.

18. Brucker RM, Harris RN, Schwantes CR, Gallaher TN, Flaherty DC, Lam BA, Gutiérrez-Román M, Holguín-Meléndez F, Dunn MF, Guillén-Navarro K, Huerta-Palacios G. Antifungal Activity of Serratia marcescens CFS5-B2 purified chitoitinolytic enzymes and prodigiosin against Mycoplasmella fijennis, causative agent of black Sigatoka in banana (Musa spp.). BioControl. 2015;60(4):565–72.

19. Somaya N, Katakga N, Komagata T, Hayare K, Hibi T, Akutsu K. Biological Potential and Mechanism of Prodigiosin from Serratia marcescens D1 with its host and non-host fung. PLoS One. 2020;15(4): e024051.

20. Li WJ, Zhang YQ, Park DJ, Li CT, Xu LH, Kim CJ, Jiang CL. Duganella cinereus. J Chem Ecol. 2008;34(11):1422–32.

21. Lanes J, Jarque LA, Flechas SV, Forman ME, Iannetta AA, Joyce MD, et al. Prodigiosin, Violacin, and Volatile Organic Compounds Produced by Widespread Cutaneous Bacteria of Amphibians Can Inhibit Two Batrachochytrium Fungal Pathogens. Microb Ecol. 2018;75(4):1049–62.

22. Moreno N, Nakajima M, Hayare K, Hibi T, Akutsu K. Synergistic Antifungal Activity of Chitinolytic Enzymes and Prodigiosin Produced by Biotocell Bacterium, Serratia marcescens Strain B2 against Gray Mold Pathogen, Botrytis cinerea. J General Plant Pathol. 2001;67(4):312–7.

23. Keita J, Jinnah P, Sreeleka Chithra S, Radhakrishnan EK. Antifungal properties of prodigiosin producing rhizospheric Serratia sp. Rhizosphere. 2017;3:105–8.

24. Yada S, Wang Y, Zou Y, Nagasaki K, Hosokawa K, Osaka I, Arakawa R, Enamoto K. Isolation and characterization of two groups of novel marine bacteria producing violacin. Mar Biotechnol. 2008;10(2):128–32.

25. Moss MO, Ryall C, Logan NA. Classification and Characterization of Chromobacteria from a Lowland River. J Gen Microbiol. 1978;105(3):11–21.

26. Otsuljan J, Mccollough J, Johnson JH, Bonner DP, Clark JC, Dean L, Trejo WH. Janthinocin-a, Janthinocin-b and Janthinocin-c, Novel Peptide Lactone Antibiotics Produced by Janthinobacterium-Biludium. J Taxonomy, Fermentation, Isolation, Physicochemical and Biological Characterization. J Antibiot. 1990;43(8):913–9.

27. Yada S, Wang Y, Zou Y, Nagasaki K, Hosokawa K, Osaka I, Arakawa R, Enamoto K. Isolation and characterization of two groups of novel marine bacteria producing violacin. Mar Biotechnol. 2008;10(2):128–32.

28. Rivas O, Hauen M, Duran N. Effect of Growth-Conditions on Production of Violacin by Chromobacterium-Violaceum (Bb-78 Strain). Braz J Med Biol Res. 1988;21(5):553–60.
63. Asencio G, Paris Lavin, Karen Alegrà a, et al. Antibacterial activity of the
64. Cazoto LL, Martins D, Ribeiro MG, Duran N, Nakazato G. Antibacterial activity
65. Lozano GL, Guan C, Cao Y, Borlee BR, Broderick NA, Stabb EV, Handelsman J.
66. Bilsland E, Tavella TA, Krogh R, Stokes JE, Roberts A, Ajioka J, Spring DR,
67. Leon LL, Miranda CC, De Souza AO, Duran N. Antileishmanial activity of the
68. Hornung C, Poehlein A, Haack FS, Schmidt M, Dierking K, Pohlen A,
69. Andrighetti-Frohner CR, Antonio RV, Creczynski-Pasa TB, Barardi CRM,
70. glutamicum for violacein hyper production. Microb Cell Fact. 2016;15(1):148.
71. Antibiot. 2011;64(5):395–403.
72. Antiparasitic activity of microbial pigments and their
73. Ballestriero F, Daim M, Penesyan A, Nappi J, Schleheck D, Bazzicalupo P, Di
74. Hazarika DJ, Gautom T, Parveen A, Goswami G, Barooah M, Modi MK, Boro RC.
75. Kimyon Ö, Das T, Ibugo Al, Kutty SK, Ho KK, Tebben J, Kumar N, Manefield M. Seratia Secondary Metabolite Prodigiosin Inhibits Pseudomonas aeruginosa Biofilm Development by Producing Reactive Oxygen Species that Damage Biological Molecules. Front Microbiol. 2020;11:107614.
76. Prabhu VV, Hong B, Allen JE, Zhang S, Lulla AR, Dicker DT, El-Deiry WS. Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Human Lung Cancer Cells. Ann New York Acad Sci. 2003;1010(1):178-181.
77. Campas C, Dalmau M, Montaner B, Baragán M, Bellosillo B, Colomer D, Pons G, Pérez-Tomás R, Gil J. Prodigiosin induces apoptosis in breast cancer cells by activating p73. Cancer Res. 2016;76(7):1989-99.
88. Cheng S-Y, Chen N-F, Kuo H-M, Yang S-N, Sung C-S, Sung P-J, Wen Z-H, Chen W-F. Prodigiosin stimulates endoplasmic reticulum stress and induces autophagic cell death in glioblastoma cells. Apoptosis. 2018;23(3):314–28.

89. Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol. 2005;69(3):407–14.

90. Sessler A, Elfer LR, Cho W-S, Nicolaou S, Aqular A, Lee JT, Lynch VM, Magda DJ. Synthesis, Anion-Binding Properties, and In Vitro Anticancer Activity of Prodigiosin Analogaes. Angewandte Chemie Internat Ed. 2005;44(37):5989–92.

91. Zhao C, Qu S, He J, Feng Y, Xu HM, Feng ZQ, Huang HQ, Du YL, Zhou YJ, Nie YQ. Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death. Cancer Lett. 2020;481:15–23.

92. Montaner B, Castillo-Avila W, Martinell M, Öllinger R, Aymami J, Giralt E, Simon J, Zanetti L, Cenci G. The effect of prodigiosin on the activities of protein phosphatases Tyrosine Phosphatase Inhibitors. ChemBioChem. 2004;5(11):1575–86.

93. Rekabi K, Suleiman A, Alshatwi AA, Subash-Babu P, Antonisamy P. Violacein induces apoptosis in gastric cancer cell line SGC7901. J Med Food. 2013;16(4):297–306.

94. Alshatawi AA, Subash-Babu P, Antonisamy P. Violacein induces apoptosis in gastric cancer cell line SGC7901. J Med Food. 2013;16(4):297–306.

95. Antonisamy P, Kannan P, Aravinthan A, Duraipandiyan V, Arasu MV, Ramakrishnan R. Gastroprotective activity of violacein against ischemia reperfusion-induced gastric lesions in rats: investigation of potential mechanisms of action. SciWorldJournal. 2014;2014:616432.

96. Han SB, Kim HM, Kim YH, Lee CW, Jang ES, Son KH, Kim SJ, Kim YK. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int J Immunopharmac. 1998;20(1):1–3.

97. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J Pharmacol Exp Ther. 2001;299(2):415–25.

98. Mortellaro A, Songia S, Gnocchi P, Ferrari M, D’Alessio R, Isetta A, Colotta F, Golay J. New immunosuppressive drug PNU156804 blocks IL-2-induced proliferation and NF-kappa B and AP-1 activation. J Immunol. 2005;175(12):7102–7.

99. Han SB, Lee CW, Yoon YD, Kang JS, Lee K, Yoon KH, Yoon WK, Lee YK, Park SK, Kim HM. Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem Pharmacol. 2005;70(10):1518–26.

100. Huh J-E, Koo H-J, Kim K-H, Yim J-H, Lee H-K, Sohn E-W, Pyo S-N. Prodigiosin induces death of RAS-mutated metastatic breast cancer cells via inducing autophagic cell death in glioblastoma cells. Apoptosis. 2012;17(9):1299–314.

101. Aoki Y, Copeland A, Hagemeister F, Hagemeister B, Fanale M, Romaguera J, Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, Somfay A. Inhibition of tumor invasion. Biochem Pharmacol. 2005;69(3):407–14.

102. Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Apoptosis. 2018;23(2):93–112.

103. Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, Somfay A, Zatolka P, Kazmovicz A, Moezi MM, et al. Randomized phase II study of carbolamin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85(3):420–8.

104. Antonisamy P, Kannan P, Aravinthan A, Duraipandiyan V, Arasu MV, Ignacimuthu S, Al-Dhabi NA, Kim JH. Gastroprotective activity of violacein isolated from Chromobacterium violaceum on indomethacin-induced gastric lesions in rats: investigation of potential mechanisms of action. SciWorldJournal. 2014;2014:616432.

105. Alshatwi AA, Subash-Babu P, Antonisamy P. Violacein induces apoptosis in human breast cancer cells through up-regulation of BAX, p53 and down-regulation of MDM2. Exp Toxicol Pathol. 2016;68(10):1518–26.

106. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J Pharmacol Exp Ther. 2001;299(2):415–25.

107. Huh J-E, Koo H-J, Kim K-H, Yim J-H, Lee H-K, Sohn E-W, Pyo S-N. Prodigiosin induces death of RAS-mutated metastatic breast cancer cells via inducing autophagic cell death in glioblastoma cells. Apoptosis. 2012;17(9):1299–314.

108. Antonisamy P, Ignacimuthu S. Immunomodulatory, analgesic and antipyretic effects of violacein isolated from Chromobacterium violaceum. Phytomed. 2010;17(3-4):300–4.

109. Verinaud L, Lopes SC, Prado IC, Zanucoli F, Alves da Costa T, Di Gangi R, Issayama LK, Carvalho AC, Bonfant AC, Niederauer GF, Duran N, Costa FT, Oliveira AL, Hoffing MA, Machado DR, Thomé R. Violacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T Cells. PLoS One. 2015;10(5):e0125409.

110. Althawi AA, Subash-Babu P, Antonisamy P. Violacein induces apoptosis in human breast cancer cells through up regulation of BAX, p53 and down regulation of MDMD. Exp Toxicol Pathol. 2016;68(1):89–97.

111. Kuziemski F, Kollisch G, Mark K, Diesfeldt WE, Kaufmann A, Bauer S, Chavarría M, Araya JJ, García-Piñeres AJ. The Bacterial Product Violacein Exerts an Immunostimulatory Effect Via TLR8. Sci Rep. 2019;9(1):13661.

112. Dornmoes A, Klein AS, Hage-Hülsmann J, Thies S, Svensson Y, Classen T, Pietrusza J, Jaeger KE, Dreyper T, Loeschke A. Efficient recombinant
production of prodigiosin in Pseudomonas putida. Front Microbiol. 2015;6:972.

131. Gallardo K, Candia JE, Remonsette E, Escudero LV, Demergasso CS. The Ecological Coherence of Temperature and Salinity Tolerance Interaction and Pigmentation in a Non-marine Vibriob isolated from Salar de Atacama. Front Microbiol. 2016;7:1943.

132. Song MJ, Bae J, Lee DS, Kim CH, Kim JS, Kim SW, Hong SJ. Purification and characterization of prodigiosin produced by integrated bioreactor from Serratia sp KH-95. J Biosci Bioeng. 2006;102(12):157–61.

133. Williams RP, Gott CL, Green JA. Studies on Pigmentation of Serratia Marcescens. V. J Bacteriol. 1961;81(3):376–9.

134. Elahian F, Moghimi B, Dinmohammadi F, Ghamghami M, Hamidi M, Mirzaei SA. The Anticancer Agent Prodigiosin Is Not a Multidrug Resistance Protein Substrate. DNA and Cell Biology. 2013;32(3):90–7.

135. Mendes AS, de Carvalho JE, Duarte MCT, Duran N, Bruns RE. Factorial design and response surface optimization of crude violacein for Chromobacterium violaceum production. Biotechnol Lett. 2001;23(23):1963–9.

136. Pantanella F, Berluti F, Passanietti C, Sarli S, Morea C, Schippa S. Violacein synthesis and separation. Nature. 2020;586(7827):57–61.

137. DeMoss RD. Violacein. In: Biosynthesis; 1967. p. 77–81.

138. Rodriguez AM, Trachtmann N, Becker J, Lohanatha AF, Blotenberg J, Bolten CJ, Korneli C, Lima AOD, Porto LM, Sprenger GA, et al. Systems metabolic engineering of Escherichia coli for production of the antitumor drug violacein and deoxyviolacein. Metab Eng. 2013;20:24–31.

139. Choi SY, Yoon KH, Lee J, Mitchell RJ. Violacein: Properties and Production of a Versatile Bacterial Pigment. Biomed Res Int. 2015;2015:465056.

140. Wang HS, Jiang PX, Lu Y, Ruan ZY, Jiang RB, Xing XH, Lou K, Wei D. Characterization of Violacein by Locally Isolated Chromobacterium violaceum Grown in Agricultural Wastes. Appl Biochem Biotechnol. 2012;166(1):187–95.

141. Fineran PC, Slater H, Eversen L, Hughes K, Salmson GPC. Biosynthesis of tripyrrole and β-lactam secondary metabolites in Serratia integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carabapenem antibiotic production. Mol Microbiol. 2005;56(4):971–89.

142. Williams RP, Goldschmidt ME, Gott CL. Inhibition by temperature of the terminal step in biosynthesis of prodigiosin. Biochim Biophys Acta. 1965;19(2):177–81.

143. Morrison DA. Prodigiosin synthesis in mutants of Serratia marcescens. J Bacteriol. 1966;91(4):1599–604.

144. Qadri SM, Williams RP. Role of Methionine in Biosynthesis of Prodigiosin by Serratia marcescens. J Bacteriol. 1973;116(3):1191–8.

145. Pantanella F, Berluti F, Passanietti C, Sarli S, Morea C, Schippa S. Violacein and biofilm production in Janthinobacterium lividum. J Appl Microbiol. 2007;102(4):992–9.

146. Aruldass CA, Venil CK, Zakaria ZA, Ahmad WA. Brown sugar as a low-cost substrate for the production of violacein by Serratia marcescens FZSF02 in the form of pigment pellets. Electron J Biotechnol. 2019;20(1):658–64.

147. Koo B-S, Hahn B-S, Sim J-S, Lee C-M, Kwon S-W, Baek H-J, Yoon S-H. Enhanced production of prodigiosin by Serratia marcescens UTM1. Int Biodeterioration Biodegradation. 2014;95:19–24.

148. Kurbanoglu EB, Ozdal M, Ozdal OG, OF A. Enhanced production of prodigiosin by Serratia marcescens FZSF02 in the form of pigment pellets. Electron J Biotechnol. 2019;20(1):658–64.

149. Siva R, Subha K, Bhakta D, Ghosh AR, Babu S. Characterization and biosynthesis of two antibiotics, prodigiosin and carbapenem, in Serratia is under quorum sensing control. Mol Microbiol. 2002;36(3):539–56.

150. Salmond GPC. luxS mutants of Serratia defective in quorum sensing. Front Microbiol. 2016;7:1943–11.

151. Sanchez C, Brana AF, Mendez C, Salas JA. Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis. Chembiochem. 2006;7(8):1231–40.

152. Balbar CJ, Walsh CT. In vitro biosynthesis of violacein from L-tryptophan by the enzymes ViK-E from Chromobacterium violaceum. Biochemistry-U. 2006;45(51):15444–57.

153. August PR, Grossman TH, Minor C, Draper MP, Maclell J, Pemberton JM, CaK MH, Holt D, Osborne MS. Sequence analysis and functional characterization of the violacein biosynthetic gene-Cluster from Chromobacterium-violaceum. Curr Microbiol. 1991;22(6):355–8.

154. Williamson NR, Simonsen HT, Ahmed RAA, Goldet G, Slater H, Woodley L, Leeper FJ, Salmson GPC. Biosynthesis of the red antibiotic, prodigiosin, in Serratia: Identification of a novel 2-methyl-3-n-arylpyrrole (MAPP) assembly pathway, definition of the terminal condensing enzyme and implications for undecapridigoisin biosynthesis in Strepomyces. Mol Microbiol. 2005;56(4):971–89.

155. Williams RP, Goldschmidt ME, Gott CL. Inhibition by temperature of the terminal step in biosynthesis of prodigiosin. Biochim Biophys Acta. 1965;19(2):177–81.

156. Thomson NR, Crow MA, McGowan SJ, Cox A, Salmson GPC. Biosynthesis of carabapenem antibiotic and prodigiosin pigment in Serratia is under quorum sensing control. Mol Microbiol. 2008;47(2):303–20.

157. Qadri SM, Williams RP. Role of Methionine in Biosynthesis of Prodigiosin by Serratia marcescens. J Bacteriol. 1973;116(3):1191–8.

158. Fineran PC, Slater H, Eversen L, Hughes K, Salmson GPC. Biosynthesis of tripyrrole and β-lactam secondary metabolites in Serratia integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carabapenem antibiotic production. Mol Microbiol. 2005;56(4):971–89.

159. Slater H, Crow M, Eversen L, Salmson GPC. Phosphate availability regulates biosynthesis of two antibiotics, prodigiosin and carabapenem, in Serratia via both quorum-sensing-dependent and -independent pathways. Mol Microbiol. 2008;47(2):303–20.

160. Panchella F, Berluti F, Passanietti C, Sarli S, Morea C, Schippa S. Violacein and biofilm production in Janthinobacterium lividum. J Appl Microbiol. 2007;102(4):992–9.

161. Coulthurst SJ, Kutz CL, GPC S. luxS mutants of Serratia defective in autoinducer-2-dependent ‘quorum sensing’ show strain-dependent impacts on virulence and production of carabapenem and prodigiosin. Microbiology. 2004;150(6):1901–10.

162. Pemberton JM, Vincent KM, Penfold RJ. Cloning and Heterologous Expression of the Violacin Biosynthesis Gene-Cluster from Chromobacterium-violaceum. Curr Microbiol. 1991;22(6):355–8.

163. Madhusudan K, Nadendla UM. A review of violacein: the first and the foremost antibiotic. Curr Top Med Chem. 2007;7:1958–61.

164. Fukushima A, Murakami C, Anzai Y, Kato F. Marinovincins: new quorum-sensing inhibitors against Chromobacterium violaceum CV026 were isolated from Streptomyces sp. TOHO-M025. J Antibiot (Tokyo). 2016;69(5):395–9.

165. Ohita T, Fukushima A, Izaka Y, Kato F, Koyama Y, Anzai Y. Quorum Sensing Inhibitors against Chromobacterium violaceum CV026 Derived from an Actinomycete Metabolite Library. Biol Pharm Bull. 2020;43(1):179–83.

166. Harrison AM, Soby SD. Reclassification of Chromobacterium violaceum as ATCC 31532 and its quorum biosensor mutant CV026 to Chromobacterium subsutus. AMB Express. 2020;10(1):202.

167. Su C, Xiang Z, Liu Y, Zhao X, Sun Y, Li Z, Liang F, Chen F, Teng W, Xue Z, Zhou Y, Zhao F. Analysis of the genomic sequences and metabolites of Serratia surfacantafaciens sp. nov. YDS27 that simultaneously produces prodigiosin and serawettin W2. BMC Genomics. 2016;17(1):865.

168. Li P, Kwok AH, Jiang J, Ran T, Xu D, Wang W, Leung FC. Comparative genome analyses of Serratia marcescens FS14 reveals its high antigenic potential. PLoS One. 2015;10(4):e0123061.

169. Smith HJ, Foreman CM, Akijama T, Franklin MJ, Devitt NP, Ramaraj T. Genome Sequence of Janthinobacterium sp. CG23_2, a Violacin-Producing
174. Valdes N, Soto P, Cottet L, Alarcon P, Gonzalez A, Castillo A, Corsini G, Tello M. Draft genome sequence of Janthinobacterium lividum strain MTR reveals its mechanism of capnophilic behavior. Stand Genomic Sci. 2015;10:110.

175. Wu X, Deutschbauer AM, Kazakov AE, Wetmore KM, Cwick BA, Walker RM, Novichkov PS, Arkin AP, Chakraborty R. Draft Genome Sequences of Two Janthinobacteriumlividum Strains, Isolated from Pristine Groundwater Collected from the Oak Ridge Field Research Center. Genome Announc. 2017;5(26):e00582-17.

176. Doing G, Perron GG, Jude BA. Draft Genome Sequence of a Violacein-Producing Lactobacter sp. from the Hudson Valley Watershed. Genome Announc. 2018;6(1):e01428-17.

177. Jude BA. Draft Genome Sequence of a Chitinimonas Species from Hudson Valley Waterways That Expresses Violacein Pigment. Microbiol Resour Announc. 2019;8(35):e00683-19.

178. Lamendella R, Jude BA. Draft Genome Sequences of Violacein-Producing Duganella sp. Isolates from a Waterway in Eastern Pennsylvania. Microbiol Resour Announc. 2018;7(12):e01195-18.

179. Bettina AM, Doing G, O’Brien K, Perron GG, Jude BA. Draft Genome Sequences of Phenotypically Distinct Janthinobacterium sp. Isolates Cultured from the Hudson Valley Watershed. Genome Announc. 2018;6(3):e01426-17.

180. O’Brien K, Perron GG, Jude BA. Draft Genome Sequence of a Red-Pigmented Janthinobacterium sp. Native to the Hudson Valley Watershed. Genome Announc. 2018;6(1):e01429-17.

181. Kwon SK, Park YK, Kim JF. Genome-wide screening and identification of factors affecting the biosynthesis of prodigiosin by Hahella chejuensis, using Escherichia coli as a surrogate host. Appl Environ Microbiol. 2010;76(5):1661–8.

182. Dauenhauer SA, Hull RA, Williams RP. Cloning and expression in Escherichia coli of Seratia marcescens genes encoding prodigiosin biosynthesis. J Bacteriol. 1984;158(3):1128–32.

183. Fang MY, Zhang C, Yang S, Cui JY, Jiang PX, Lou K, Wachi M, Xing XH. High crude violacein production from glucose by Escherichia coli engineered with interactive control of tryptophan pathway and violacein biosynthetic pathway. Microb Cell Fact. 2015;14(1):8.

184. Immanuel SRC, Banerjee D, Rajankar MP, Raghunathan A. Integrated constraints based analysis of an engineered violacein pathway in Escherichia coli. Biosystems. 2018;171:10–18.

185. Rodrigues AL, Göcke Y, Bolten C, Brock NL, Dickshat JS, Wittmann C. Microbial production of the drugs violacein and deoxyviolacein: analytical development and strain comparison. Biotechnol Lett. 2011;34(4):717–20.

186. Wilkinson MD, Lai HE, Freemont PS, Baum J. A Biosynthetic Platform for Antimalarial Drug Discovery. Antimicrob Agents Chemother. 2020;64(5):e02129-19.

187. C-Y H, Guo Y, Liu L, Zhang N-X, Gao C-X, Yang X-Q, Yi J. Genetic control of violacein biosynthesis to enable a pigment-based whole-cell lead biosensor. Rsc Adv. 2020;10(47):28106–13.

188. Jiang Y, Signum F, Reber J, Dein-Ben XL, Glad S, Kniepp M, Estrada H, Razansky D, Ntzachristos V, Westmeyer GG. Violacein as a genetically controlled, enzymatically amplified and photobleaching-resistant chromophore for optoacoustic bacterial imaging. Sci Rep. 2015;5:11048.

189. Jeschek M, Gerngross D, Panke S. Rationally reduced libraries for combinatorial pathway optimization minimizing experimental effort. Nat Commun. 2016;7:11163.

190. Chuang J, Boeke JD, Mitchell LA. Coupling Yeast Golden Gate and VEGAS for Efficient Assembly of the Violacein Pathway in Saccharomyces cerevisiae. In: Synthetic Metabolic Pathways; 2018. p. 211–25.

191. Tong Y, Zhou J, Zhang L, Xu P. A Golden-Gate Based Cloning Toolkit to Build Violacein Pathway Libraries in Yarrowia lipolytica. ACS Synthetic Biol. 2021;10(1):115–24.

192. NCBI PubMed https://pubmed.ncbi.nlm.nih.gov/. Accessed 20 Jan 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.